Context Therapeutics Inc

NASDAQ:CNTXUnited States

Context Therapeutics Inc. is a biopharmaceutical company advancing medicines for solid tumors. The Company is building an advanced portfolio of clinical-stage T cell engaging bispecific therapeutics, including CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody, and CT-95, a potential first-in-class mesothelin x CD3 bispecific antibody. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors, including ovarian, endometrial, testicular, and lung, and absent from or expressed at low levels in healthy adult tissues. CTIM-76 is capable of binding to tumor cells expressing CLDN6 and stimulating intra-tumoral T cells by the CD3 arm that is designed to be activated only upon tumor engagement while silent elsewhere. CTIM-76 has the potential for a wide therapeutic window. The Company’s CT-95 is being developed as a therapy for advanced cancers associated with mesothelin (MSLN) expression.

Contact Information

Headquarters

2001 Market Street, Suite 3915 Unit #15PHILADELPHIA, PA, United States 19103

Phone

267-225-7416

Fax

302-655-5049

Executives

Independent Chairman of the Board

Richard Berman

President, Chief Executive Officer, Director

Martin Lehr

Chief Financial Officer, Treasurer

Jennifer Minai-Azary

Senior Vice President - Operations

Christopher Beck

Vice President - Clinical Operations

Karen Andreas